<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072341</url>
  </required_header>
  <id_info>
    <org_study_id>Hospital São Rafael S.A</org_study_id>
    <nct_id>NCT04072341</nct_id>
  </id_info>
  <brief_title>Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients.</brief_title>
  <official_title>Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients: a Randomized Cross-over Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alagoas State University of Health Science , Maceió , Brazil.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      End-stage chronic kidney disease is associated with the condition of chronic inflammation.
      Patients on hemodialysis are known to be predisposed to several factors that predispose to
      inflammation: dialysis membranes, central venous catheters, oxidative stress, fluid overload,
      sodium overload, uraemic toxins. Propolis, a natural resin produced by bees from plant
      materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties. The aim of
      this study was to evaluate the impact of Brazilian green propolis extract on inflammation in
      hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized open-label cross-over trial to investigate impact of Brazilian green propolis
      extract on inflammation in hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized Cross-Over Trial. Each patient served as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum level of High-sensitivity C-reactive protein from baseline to end of study periods.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in high sensitivity C-reactive protein from baseline to end of study periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum level of Interleukin-1 Beta from baseline to end of study periods.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Interleukin-1 Beta from baseline to end of study periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum level of alanine aminotransferase, aspartate aminotransferase, amylase and creatine kinase during the study, from baseline to end of study periods.</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the safety of propolis use in hemodialysis patients. Measurement of changes in serum level of alanine aminotransferase, aspartate aminotransferase, amylase and creatine kinase during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events during the study.</measure>
    <time_frame>8 weeks</time_frame>
    <description>We will evaluate the presence or absence of symptoms related to the use of propolis through a questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Propolis Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propolis Period (Green Propolis 250mg/day)</intervention_name>
    <description>Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.</description>
    <arm_group_label>Propolis Period</arm_group_label>
    <other_name>Standard treatment for their comorbidities.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Period</intervention_name>
    <description>In the control period they will only follow standard treatment for their comorbidities.</description>
    <arm_group_label>Control Period</arm_group_label>
    <other_name>Standard treatment for their comorbidities.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years;

          -  Male or female on hemodialysis for at least 1 month.

        Exclusion Criteria:

          -  Pregnant Woman;

          -  Carriers of active neoplasms;

          -  Patients undergoing kidney transplantation during the study;

          -  Infection during the study;

          -  Patients who underwent parathyroidectomy during the study;

          -  Patient using immunosuppressive drugs;

          -  Allergy to propolis or any of its components;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Silveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Rafael S.A</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flávio Teles, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual de Ciências da Saúde de Alagoas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rogério Passos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Rafael S.A</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo Silveira</last_name>
    <phone>+55 71 3408-8000</phone>
    <email>marceloadsilveira@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rogerio Passos</last_name>
    <phone>+55 71 3408-8000</phone>
    <email>rogerio.passos@hsr.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marcelo Augusto Duarte Silveira</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Silveira, MD, PhD</last_name>
      <phone>+55 71 3409-8000</phone>
      <email>marceloadsilveira@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Teles F, da Silva TM, da Cruz Júnior FP, Honorato VH, de Oliveira Costa H, Barbosa AP, de Oliveira SG, Porfírio Z, Libório AB, Borges RL, Fanelli C. Brazilian red propolis attenuates hypertension and renal damage in 5/6 renal ablation model. PLoS One. 2015 Jan 21;10(1):e0116535. doi: 10.1371/journal.pone.0116535. eCollection 2015.</citation>
    <PMID>25607548</PMID>
  </reference>
  <reference>
    <citation>Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. Contrib Nephrol. 2017;191:32-43. doi: 10.1159/000479254. Epub 2017 Sep 14. Review.</citation>
    <PMID>28910789</PMID>
  </reference>
  <results_reference>
    <citation>Silveira MAD, Teles F, Berretta AA, Sanches TR, Rodrigues CE, Seguro AC, Andrade L. Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial. BMC Nephrol. 2019 Apr 25;20(1):140. doi: 10.1186/s12882-019-1337-7.</citation>
    <PMID>31023272</PMID>
  </results_reference>
  <results_reference>
    <citation>Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii35-iii40. doi: 10.1093/ndt/gfy175. Review.</citation>
    <PMID>30281126</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Marcelo Augusto Duarte Silveira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Propolis</keyword>
  <keyword>High-sensitivity C-reactive protein</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propolis</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

